Answers are grounded in this paper and cite their sources.
Background Malignant peritoneal mesothelioma (MPM) is a rare disease with a generally poor prognosis treated with systemic chemotherapy alone. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can offer improved overall survival in select patients. This study examined the effect of travel distance on oncologic outcomes in patients with MPM undergoing CRS-HIPEC. Methods The National Cancer Database (NCDB) was reviewed from 2006 to 2020. The primary variable was distance traveled to CRS-HIPEC facility (<50 miles versus ≥50 miles). Primary outcome was overall survival. Secondary outcomes examined 30- and 90-day post-surgical outcomes. Results Overall, 650 patients met inclusion criteria; 345 patients traveled < 50 miles and 305 patients traveled ≥ 50 miles. Rates of MPM were highest in the Northeast, Middle and South Atlantic regions. Patients traveling ≥50 miles were younger, had a lower median income, and were more likely to be privately insured and treated at an academic center. There was no difference in overall survival between groups (p=0.87). Secondary outcomes were comparable: 30-day survival was 98 % in both groups (p=0.9), 90-day survival was 93 % in both groups (p=0.9), 30-day readmission rate was 11 % in the shorter travel distance group versus 7 % (p=0.2). Hospital length of stay (LOS) was longer in the ≥50 miles group (9 vs 8 days; p=0.02). Conclusions Outcomes following CRS-HIPEC for MPM did not differ based upon distance traveled for treatment, though patients who travel ≥ 50 miles have an increased LOS. Regionalization of CRS-HIPEC for MPM does not result in worse oncologic or surgical outcomes.
No takes yet. Share an insight, caveat, or question.
Sadjadi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: